BMAC Treatment: Bone Marrow Concentrate Explained

What to establish in a consultation

Ask where marrow is collected, what processing system is used and what is measured in the final preparation. Clarify whether it is injected alone or combined with another procedure, and whether the clinic is proposing BMAC or a different cell product.

Collection and joint administration are separate steps. Ask who performs each one, what pain control is planned and how the team manages complications. Obtain the complete treatment plan before comparing prices.

Evidence: symptom relief is not cartilage regeneration

AAOS notes that evidence for orthopaedic cell treatments remains limited and mixed. A claim that cells rebuild a knee should therefore be examined much more closely than a general statement that some patients report less pain. Ask what the study actually measured and whether it used the same preparation. AAOS patient information.

Compare the whole treatment plan

Record whether the proposed injection is accompanied by arthroscopy, rehabilitation, a platelet preparation or other treatment. Ask how those elements may contribute to the outcome. The effect of a combined pathway cannot automatically be assigned to BMAC alone.

Your comparison should include the marrow collection procedure, administration site, planned observation and follow-up assessment. Ask what additional tests or imaging would change the recommendation, and whether you can discuss the proposal with your usual orthopaedic clinician before paying.

Knee symptoms need a diagnosis first

Persistent knee pain can lead patients to search for regenerative treatments, but a treatment label is not a diagnosis. Ask a specialist to explain the relevant examination and imaging findings and the reasonable alternatives for your situation.

A report of benefit in a study does not guarantee benefit for your severity of disease or the proposed protocol. Ask about controlled comparisons, follow-up duration and outcomes that matter to you, such as walking and daily function.

Do not confuse it with Cartistem

MEDIPOST describes Cartistem as an allogeneic umbilical cord blood-derived cell product with Korean approval for specified knee cartilage defects. It is not a generic synonym for marrow concentrate. Ask which treatment is part of your proposed care plan.

Sources and further reading

1. MEDIPOST — Cartistem product information (manufacturer)Source checked 9 October 2026.
2. ISSCR — Patient resourcesSource checked 9 October 2026.
3. AAOS OrthoInfo — Use of stem cells in orthopaedicsSource checked 9 October 2026.